Anti-CD19 CAR-T Cells (eGFP)

Catalog #

78789

$1,650 *

Size: 1 vial

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Anti-CD19 CAR-T Cells (eGFP) were produced by high-titer lentiviral transduction of human primary CD4⁺ and CD8⁺ T cells with SIN Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ eGFP) (#78775). These ready-to-use CAR (Chimeric Antigen Receptor)-T cells express an anti-CD19 CAR consisting of the ScFv (Single chain fragment variable) of anti-CD19 (clone FMC63) linked to a 2^nd generation CAR containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1). The presence of eGFP (enhanced green fluorescent protein) allows for easy fluorescent detection of CAR-expressing cells.

These CAR-T cells have been validated by flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.

Figure 1. Construct diagram showing components of the anti-CD19 CAR expressed in Anti-CD19 CAR-T Cells (eGFP).

●

Synonyms

B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19

●

Product Data Gallery

Assessment of expression of anti-CD19 CAR and eGFP in Anti-CD19 CAR-T Cells (eGFP) by flow cytometry

Luciferase-based cytotoxicity assay using Anti-CD19 CAR-T Cells (eGFP) co-cultured with Firefly Luciferase Raji Cell Line as the target cells.

Product Info

Storage and Usage

Citations

Supplied As

Each vial contains ˃1 x 10⁶ cells in 1 ml of CryoStor® CS10 (Stemcell Technologies #100-1061)

Materials Required But Not Supplied

Name	Ordering Information
Thaw Medium 2	BPS Bioscience #60184
Human Interleukin-2 Recombinant	BPS Bioscience #90184
Human CD3/CD28/CD2 T Cell Activator	STEMCELL Technologies #10970
PE-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1	Acrobiosystems # FM3-HPY53-25tests
Firefly Luciferase Raji Cell Line	BPS Bioscience #78622
Firefly Luciferase CD19 Knockout Raji Cell Line	BPS Bioscience #82167
Untransduced T Cells (Negative Control for CAR-T cells)	BPS Bioscience #78170
ONE-Step™ Luciferase Assay System	BPS Bioscience #60690
Luminometer

Recommended Anti-CD19 CAR-T Cell Medium: TCellM™ (#78753) supplemented with 10 ng/ml Interleukin-2 (#90184).

UniProt #

P15391

Mycoplasma Testing

The cells have been screened to confirm the absence of Mycoplasma species.

Background

CD19 (Cluster of Differentiation 19), also known as B-lymphocyte surface antigen B4, or CVID3, is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency disorders associated with impaired antibody production such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia). In addition, CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.

References

Depoil D., et al., 2008 Nat Immunol. 9: 63-72.
Van Zelm M.C., et al., 2006 N Engl J Med. 354: 1901-1912.
Goebeler M.E. and Bargou R., 2016 Leuk Lymphoma 57: 1021-1032.
Braendstrup P., et al., 2020 Cytotherapy 22: 57-69.

Storage/Stability

Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at [email protected] if the cells are not frozen in dry ice upon arrival.

Applications

Use as positive control in anti-CD19 CAR-T cell development.
Screen modulators of anti-CD19 CAR-T driven cytotoxicity.
Design and optimize co-culture cytotoxicity assays for anti-CD19 specific CAR-T cell evaluation.

Shipping Temperature

-80°C

Notes

Troubleshooting Guide
Visit Cell Line FAQs for more information. For further questions, please email [email protected].

Biosafety
The anti-CD19 CAR-T cells are produced with the third generation SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle

Warnings

Donors have been screened and determined negative for:
Hepatitis B (anti-HBc EIA, HBsAg EIA)
Hepatitis C (anti-HCV EIA)
Human Immunodeficiency Virus (HIV-1/HIV-2 plus O)
Human T-Lymphotropic Virus (HTLV-I/II)
HIV-1/HCV/HBV
West Nile Virus
Trypanasoma cruzi

Note: Testing cannot guarantee that any sample is completely virus-free. These cells should be treated as potentially infectious and appropriate Biological Safety Level 2 (BSL-2) precautions should be used.

Scientific Category

Cancer Therapy Target

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Anti-CD19 CAR-T Cells (eGFP)

PRODUCTS

SERVICES

RESOURCES

COMPANY